02325nas a2200265 4500000000100000008004100001653003900042653002000081653000900101653001600110653001600126653001700142653001300159653001200172653001100184100001500195700001200210700001400222245013300236856007300369300000700442490000700449520158900456022001402045 2012 d10aNeglected tropical diseases (NTDs)10aRiver blindness10aNGOs10aEmpowerment10aCommunities10acase studies10aCameroon10aNigeria10aUganda1 aMeredith S1 aCross C1 aAmazigo U00aEmpowering communities in combating river blindness and the role of NGOs: case studies from Cameroon, Mali, Nigeria, and Uganda. uhttp://www.health-policy-systems.com/content/pdf/1478-4505-10-16.pdf a160 v103 a

The control of onchocerciasis is not only a major success story in global health, but also one of the best examples of the power of public-private partnership at the international level as well as at the national level. The onchocerciasis story is also a leading example of the contribution of a group of called Non-Governmental Development Organizations (NGDO) to operational research which resulted in important changes in treatment strategies and policies.The four case studies presented here illustrate some key contributions the NGDOs made to the development of "community directed treatment with ivermectin" -CDTI, in Africa, which became the approved methodology within the African Programme for Onchocerciasis Control (APOC). The partnership between the international, multilateral, government institutions and the NGDO Coordination Group was the backbone of the APOC programme's structure and facilitated progress and scale-up of treatment programmes. Contributions included piloting community-based methodology in Mali and Nigeria; research, collaboration and coordination on treatment strategies and policies, coalition building, capacity building of national health workforce and advocacy at the national and international level. While the Onchocerciasis Control Programme (OCP) and APOC provided leadership, the NGDOs working with the national health authorities played a major role in advocacy evolving the community methodology which led to achieving and maintaining- treatments with ivermectin for at least 20 years and strengthening community health systems.

 a1478-4505